Pulmonx Corp
LUNG
Company Profile
Business description
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Contact
700 Chesapeake Drive
RedwoodCA94063
USAT: +1 650 364-0400
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
291
Stocks News & Analysis
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,243.00 | 9.00 | 0.10% |
| CAC 40 | 7,703.90 | 58.70 | -0.76% |
| DAX 40 | 23,902.21 | 137.71 | -0.57% |
| Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
| FTSE 100 | 9,187.34 | 29.48 | -0.32% |
| HKSE | 25,077.62 | 78.80 | 0.32% |
| NASDAQ | 21,455.55 | 249.61 | -1.15% |
| Nikkei 225 | 42,718.47 | 110.32 | -0.26% |
| NZX 50 Index | 12,930.73 | 27.65 | 0.21% |
| S&P 500 | 6,460.26 | 41.60 | -0.64% |
| S&P/ASX 200 | 8,973.10 | 4.10 | 0.05% |
| SSE Composite Index | 3,857.93 | 14.33 | 0.37% |